Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Raqib, Rubhana ^a,e   Sarker, Protim ^a,b   Mily, Akhirunnesa ^a   Alam, Nur H ^a   Arifuzzaman, Abu Saleh M ^a   Rekha, Rokeya S ^a,b   Andersson, Jan ^c   Gudmundsson, Gudmundur H ^d   Cravioto, Alejandro ^a   Agerberth, Birgitta ^b  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF ICELAND   (Iceland)

^e ICDDRB Laboratory Sciences Division   (Bangladesh)

Author keywords

Antimicrobial peptides; Butyrate; Cathelicidin; Inflammation; Innate immunity; LL 37; Pro inflammatory cytokines; Rectal mucosa; Shigellosis; Short chain fatty acids

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA DEFENSIN 1; BETA DEFENSIN 3; BUTYRIC ACID; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CREATININE; ENEMA; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; PIVMECILLINAM; PLACEBO; SODIUM CHLORIDE; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERMETHOD COMPARISON; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PUS; RANDOMIZED CONTROLLED TRIAL; RECTUM MUCOSA; RISK REDUCTION; SHIGELLOSIS; SIGMOIDOSCOPY; THERAPY EFFECT; UREA BLOOD LEVEL;

ADOLESCENT; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BUTYRATES; CLINICAL MEDICINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSENTERY, BACILLARY; ENDOSCOPY; FECES; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RABBITS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860650355     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-111     Document Type: Article

References (33)

1. Bardhan P, Faruque AS, Naheed A, Sack DA. Decrease in shigellosis-related deaths withoutShigellaspp.-specific interventions, Asia. Emerg Infect Dis 2010, 16(11):1718-1723. 10.3201/eid1611.090934, 3294502, 21029529.
2. Sansonetti PJ. Microbes and microbial toxins: paradigms for microbial-mucosal interactions III. Shigellosis: from symptoms to molecular pathogenesis. Am J Physiol Gastrointest Liver Physiol 2001, 280(3):G319-G323.
3. Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, Andersson J. Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun 1995, 63(1):289-296. 172990, 7806368.
4. Raqib R, Moly PK, Sarker P, Qadri F, Alam NH, Mathan M, Andersson J. Persistence of mucosal mast cells and eosinophils in Shigella-infected children. Infect Immun 2003, 71(5):2684-2692. 10.1128/IAI.71.5.2684-2692.2003, 153256, 12704143.
5. Niyogi SK. Shigellosis. J Microbiol 2005, 43(2):133-143.
6. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415(6870):389-395. 10.1038/415389a, 11807545.
7. Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B, Gudmundsson G. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med 2001, 7(2):180-185. 10.1038/84627, 11175848.
8. Sperandio B, Regnault B, Guo J, Zhang Z, Stanley SL, Sansonetti PJ, Pedron T. Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expression. J Exp Med 2008, 205(5):1121-1132. 10.1084/jem.20071698, 2373844, 18426984.
9. Mortensen PB, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996, 216:132-148.
10. Rabbani GH, Albert MJ, Hamidur Rahman AS, Moyenul Isalm M, Nasirul Islam KM, Alam K. Short-chain fatty acids improve clinical, pathologic, and microbiologic features of experimental shigellosis. J Infect Dis 1999, 179(2):390-397. 10.1086/314584, 9878023.
11. Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, Nasirul Islam KM, Gudmundsson GH, Andersson J, Agerberth B. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A 2006, 103(24):9178-9183. 10.1073/pnas.0602888103, 1482586, 16740661.
12. Rabbani GH, Ahmed S, Hossain I, Islam R, Marni F, Akhtar M, Majid N. Green banana reduces clinical severity of childhood shigellosis: a double-blind, randomized, controlled clinical trial. Pediatr Infect Dis J 2009, 28(5):420-425. 10.1097/INF.0b013e31819510b5, 19319017.
13. Jakobovits SL, Travis SP. Management of acute severe colitis. Br Med Bull 2005, 75-76:131-144.
14. Raqib R, Reinholt FP, Bardhan PK, Karnell A, Lindberg AA. Immunopathological patterns in the rectal mucosa of patients with shigellosis: expression of HLA-DR antigens and T-lymphocyte subsets. APMIS 1994, 102(5):371-380.
15. Cunnane G, Bjork L, Ulfgren AK, Lindblad S, FitzGerald O, Bresnihan B, Andersson U. Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. Ann Rheum Dis 1999, 58(8):493-499. 10.1136/ard.58.8.493, 1752933, 10419868.
16. Andoh A, Bamba T, Sasaki M. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. JPEN J Parenter Enteral Nutr 1999, 23(5 Suppl):S70-S73. 10.1177/014860719902300518, 10483900.
17. Butzner JD, Parmar R, Bell CJ, Dalal V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut 1996, 38(4):568-573. 10.1136/gut.38.4.568, 1383116, 8707089.
18. Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1β, and nuclear factor κB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J 2006, 82(964):130-135. 10.1136/pgmj.2005.037945, 2596699, 16461476.
19. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011, 17(12):1519-1528. 10.3748/wjg.v17.i12.1519, 3070119, 21472114.
20. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008, 27(2):104-119.
21. Raqib R, Wretlind B, Andersson J, Lindberg AA. Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J Infect Dis 1995, 171(2):376-384. 10.1093/infdis/171.2.376, 7531208.
22. Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M, Bamba T. Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-α)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol 1999, 118(1):23-29. 10.1046/j.1365-2249.1999.01038.x, 1905403, 10540155.
23. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology 2000, 118(4):724-734. 10.1016/S0016-5085(00)70142-9, 10734024.
24. Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-κB activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes IκBα. Biochem Pharmacol 2005, 70(3):394-406. 10.1016/j.bcp.2005.04.030, 15950952.
25. Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits NF-κB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002, 37(4):458-466. 10.1080/003655202317316105, 11989838.
26. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut 2000, 47(3):397-403. 10.1136/gut.47.3.397, 1728045, 10940278.
27. Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARγ activation. Biochem Biophys Res Commun 2002, 293(2):827-831. 10.1016/S0006-291X(02)00294-2, 12054544.
28. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFκB signalling. Mol Immunol 2007, 44(15):3625-3632. 10.1016/j.molimm.2007.04.010, 17521736.
29. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Inhibition of interferon γ signaling by the short chain fatty acid butyrate. Mol Cancer Res 2003, 1(11):855-862.
30. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461(7268):1282-1286. 10.1038/nature08530, 3256734, 19865172.
31. Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, Andersson J, Bergman P, Gudmundsson GH, Agerberth B, Raqib R. Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One 2011, 6(6):e20637. 10.1371/journal.pone.0020637, 3108617, 21673991.
32. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, Marcheggiano A, Pallone F, Caprilli R, Torsoli A. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000, 45(5):976-981. 10.1023/A:1005537411244, 10795763.
33. Veiga P, Gallini CA, Beal C, Michaud M, Delaney ML, DuBois A, Khlebnikov A, van Hylckama Vlieg JE, Punit S, Glickman JN, et al. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci U S A 2010, 107(42):18132-18137. 10.1073/pnas.1011737107, 2964251, 20921388.